← All trials
NCT04989140
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2021
- Primary completion
- Jul 26, 2024
- Completion date
- Jul 26, 2024
- First posted
- Aug 4, 2021
- Last posted
- Aug 19, 2021
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Peking UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
- Peking UniversityCollaborator
- Peking UniversityCollaborator
- Capital Medical UniversityCollaborator
- China Medical UniversityCollaborator
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.